Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06284486 · ClinicalTrials.gov registry record · Phase 1

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

A Phase 1 study of Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
8
Enrollment target
4
Study locations

NCT06284486: Recruiting Phase 1 study of Acute Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.

NCT06284486 is a Phase 1 study of Acute Myeloid Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06284486, a Phase 1 study of Acute Myeloid Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
8 participants
Enrollment target
4
Study locations

Study Summary

To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Venetoclax
  • DRUG Revumenib

Study Locations (4)

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Dana-Farber Cancer Center - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-09-23
Est. Completion 2028-12-30
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT06284486 shows while recruiting

NCT06284486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.

NCT06284486 reports a single indexed study location in Maryland, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT06284486 about?

NCT06284486 is a clinical study titled "A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib". To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.

What is the current status of trial NCT06284486?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-09-23. Estimated completion is 2028-12-30.

What conditions does trial NCT06284486 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT06284486?

The interventions under investigation include: Venetoclax (DRUG), Revumenib (DRUG).

Who is sponsoring clinical trial NCT06284486?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06284486 being conducted?

This trial has 4 study locations across Maryland, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06284486's enrollment target sits among peer trials

8 297th of 306 higher than 9 of 306 other Acute Myeloid Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06284486

Source: ClinicalTrials.gov NCT06284486, the US trial registry maintained by the National Library of Medicine. NCT06284486 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.